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Eero Kajantie7,8 and Hannele Laivuori1,2,9Abstract
Background: To evaluate the soluble fms-like tyrosine kinase-1 (sFlt-1), placental growth factor (PlGF), and sFlt-1/PlGF
ratio for the prediction of early- and late-onset preeclampsia in a high-risk cohort.
Methods: We studied serial serum samples collected prospectively at 12 + 0 - 14 + 0, 18 + 0 - 20 + 0, and 26 + 0 - 28 + 0
weeks + days of gestation in 6 women who developed early-onset preeclampsia (before 34 weeks of gestation) and in
21 women who developed late-onset preeclampsia (after 34 weeks of gestation) with automated ElecSys 2010
immunoanalyzer (Roche Diagnostics, Germany). Twenty-six high-risk women and 53 women without risk factors with
normal pregnancies served as controls.
Results: Serum PlGF concentrations were lower at 18 + 0 to 20 + 0, and 26 + 0 to 28 + 0 weeks of gestation in women
who developed early-onset preeclampsia compared to women who developed late-onset preeclampsia and to controls
(p < 0.05 for all comparisons). At 18 + 0 to 20 + 0 weeks of gestation area under the receiver-operating characteristic
curve (AUC) for serum PlGF was 99.8% (p = 0.0007, 95% CI 99.0-100.0). At 26 + 0 to 28 + 0 weeks of gestation serum sFlt-
1/PlGF ratio explicitly detects those women who developed early-onset preeclampsia (AUC 100.0%, p = 0.0007, 95% CI
100–100). Amongst women with late-onset preeclampsia, those who developed severe form of the disease (N = 8) had
significantly higher serum sFlt-1 concentrations at all three timepoints (p = 0.004,
p = 0.006, and p = 0.003, respectively) compared to women with non-severe form (N = 13).
Conclusions: Low serum PlGF concentration predicts early-onset preeclampsia from the second trimester and elevated
serum sFlt-1/PlGF ratio from 26 to 28 weeks of gestation. Elevated serum sFlt-1 concentration in the first trimester in
women who later develop late-onset, severe preeclampsia may suggest different etiology compared to the late-onset
non-severe form of the disease.
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Preeclampsia is one of the leading causes of maternal
and fetal morbidity and mortality. It is a multiorgan
disease, defined according to new onset hypertension
and proteinuria developing after 20 weeks of gestation
[1]. Although the pathogenesis of the disorder starts
much earlier in pregnancy, and a number of known
clinical risk factors exist (e.g. obesity, primiparity, and a* Correspondence: pia.villa@helsinki.fi
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reproduction in any medium, provided the orhistory of preeclampsia in multiparous women), there is
no established way to predict the disorder in clinical
practice.
The etiology and pathogenesis of preeclampsia is not
completely understood, but it originates in the placenta,
and maternal endothelium is the target of the disease
[2,3]. Dysregulation and imbalance of placental pro-
angiogenic and antiangiogenic vasoactive agents, soluble
fms-like tyrosine kinase 1 (sFlt-1), vascular endothelial
growth factor (VEGF), and placental growth factor (PlGF)
play a significant role in the pathogenesis [4-6].
In the early first trimester of normal pregnancy sFlt-1
concentration is over tenfold and PlGF over twofold
higher than in non-pregnant state. In pregnancies ending. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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measured at gestational weeks six to ten, are significantly
lower than in pregnancies with live birth [7]. After the first
trimester sFlt-1 stays constant and PlGF increases until
the end of the second trimester. During the last two
months of a normotensive pregnancy the level of sFlt-1
increases and the level of PlGF decreases in maternal
blood [8,9]. These changes occur earlier and are more
pronounced in women who will develop preeclampsia [8].
Moreover, these changes may be further exaggerated in
pregnancies with an early-onset of preeclampsia, and in
preeclamptic pregnancies associated with small for gesta-
tional age fetus [8]. Therefore, these vasoactive agents
may be promising biomarkers for predicting preeclampsia
in early gestation. According to earlier studies PlGF
concentrations may be significantly lower already from
the late first trimester in women who will developed
preeclampsia. Changes in the sFlt-1 concentrations occur
later [10]. Accurate prediction of preeclampsia would be
essential to identify women who benefit most from
intensive monitoring allowing rapid intervention with
therapeutic procedures when necessary. Low dose aspirin,
started before 16 weeks of gestation, may be effective in
prevention, or at least delay the onset of early-onset and
severe preeclampsia in high-risk women [11,12]. However,
it is not known who would benefit most from aspirin
treatment.
We hypothesize that PlGF and sFlt-1 can be used as
markers in the prediction of pre-eclampsia. Our aim was
to study concentrations of sFlt-1 and PlGF and their
ratio (sFlt-1/PlGF) in prospectively collected serial serum
samples in a cohort of pregnant women with clinical risk
factors for preeclampsia, and controls with special
reference to early- and late-onset disease.
Methods
The PREDO project
This nested case–control study is a part of a multidisciplin-
ary PREDO Project (Prediction and Prevention of Pre-
eclampsia) approved by the Ethics Committee of Obstetrics
and Gynecology Hospital District of Helsinki and Uusimaa.
The study cohort was collected prospectively between
September 2005 and June 2009 in ten participating
hospital maternity clinics. The PREDO Project has
been previously described in detail [11]. Briefly, we
recruited 947 pregnant women with clinical risk factors for
preeclampsia, and 117 pregnant women without known
clinical risk factors for preeclampsia served as a control
group. The recruitment took place at the time of the first
ultrasound screening at 12 + 0 to 14 + 0 (weeks + days) of
gestation in one of ten Finnish hospital maternity clinics
participating in the PREDO Project; Women’s Hospital,
Midwifery Institute (Kätilöopisto) Maternity hospital and
Jorvi Hospital at Helsinki University Central Hospital,Kanta-Häme Central Hospital, Päijät-Häme Central Hospital,
Tampere University Hospital, Kuopio University Hospital,
Northern Karelia Central Hospital, Hyvinkää Hospital and
Iisalmi Hospital. All women with a bilateral diastolic
notch in the uterine artery Doppler velocimetry at 12–14
weeks of gestation were included in the medication group
(n = 152) and randomised to acetylsalicylic acid or placebo.
All of these women gave blood samples for biochemical
analyses at three timepoints during the pregnancy. The
other women for venipuncture were selected randomly:
after a woman was included in medication group the next
participant recruited with risk factors (without aforemen-
tioned ultrasound finding) gave blood samples at three
timepoints during the pregnancy. A written informed con-
sent was obtained from all participants before entering the
study.Data collection and diagnosis of preeclampsia
Pregnancy data were collected from the medical records
of maternity clinics and hospitals. Pregnancy outcomes
were ascertained before biochemical analyses by a jury
of two medical doctors and a midwife who met face-to
-face and agreed upon the diagnosis of each participant
based on criteria described above.Subcohort for serum sFlt-1 and PlGF measurements
We included in this substudy 26 women with clinical
risk factors for preeclampsia who eventually developed
the disease. All women whose preeclampsia diagnosis
was ascertained by the jury at the time these biochemical
analyses were started, were included. Twenty-six women
with clinical risk factors but without preeclamptic preg-
nancy, chosen by computerized randomization, formed a
first control group. Fifty-three women without clinical
risk factors and without preeclamptic pregnancy formed
a second control group. One woman without clinical
risk factors developed preeclampsia and she was
included in the group of women with preeclampsia.
Preeclamptic women were categorized by the onset and
severity of the disease.
All included women were Caucasian. Definitions and
the inclusion criteria for the PREDO Project are presented
in Table 1. Severe preeclampsia was defined as systolic
blood pressure ≥ 160 mmHg and/or diastolic ≥ 110 mmHg
in two consecutive measurements and/or proteinuria > 5 g
in 24 hour urine collection.
We were able to rule out smoking as a confounding
factor, since it was an exclusion criteria for the high risk
women. For those women in the second control group,
who did not have known risk factors for preeclampsia,
smoking was not an exclusion criteria. However, all
women filled in a questionnaire concerning their
medical history. According to that, from the fifty-three
Table 1 Inclusion criteria and definitions
Inclusion criteria Early-onset
preeclampsia n = 6
Late-onset
preeclampsia n = 21
Women with risk
factors n = 26
Complications in previous pregnancies:
Preeclampsia 1 (17%) 11 (55%) 10 (38%)
(Blood pressure≥ 140 systolic and/or≥ 90 mmHg diastolic in
two consecutive measurements and proteinuria ≥0.3 g/in
24-hour urine collection or two random urine containing≥ 1+
by dipstick or one dipstick demonstrating ≥ 2+ protein)
Fetal growth restriction 3 (50%) 0 (0%) 5 (19%)
(Birthweight SD score < −2 standard deviations (SD) according
to the Finnish standards*)
Fetal death - 1 (5%) -
(>22 weeks of gestation or over 500 g)
A history of one of the following conditions:
Obesity 2 (33%) 11 (55%) 11 (42%)
(BMI over 30 kg/m3 prior to pregnancy)
Gestational diabetes - 3 (15%) 3 (12%)
(one or more abnormal values in the oral glucose tolerance test)
Chronic hypertension - 4 (20%) 3 (12%)
(≥140/90 mmHg or medication for hypertension before 20th weeks of gestation)
Age over 40 years - 1 (5%) 1 (4%)
Age under 20 years - - 1 (4%)
Inclusion criteria in the women with risk factors in the ’Prediction and Prevention of PreEclampsia’ (PREDO) Project.
1. Early preeclampsia is diagnosed before 34 + 0 weeks of gestation.
2. Late onset preeclampsia is diagnosed after 34 + 0 weeks of pregnancy.
3. Additional inclusion criteria were Sjögren´s syndrome, systemic lupus erythematosus, type I diabetes which however were present in none of the participants.
4. Exclusion criteria were asthma, allergy to aspirin, tobacco smoking during pregnancy, previous peptic ulcer, placental ablation in a previous pregnancy,
inflammatory bowel disease (Crohn’s disease, ulcerative colitis), rheumatoid arthritis, bleeding disorder, trombophilia (previous venous or pulmonary thrombosis
and/or coagulation abnormality), or multiple pregnancy.
* According to the Finnish standards by Pihkala et al. Duodecim 1989 (13).
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the index pregnancy.
Sample collection and assays
Blood samples were drawn from antecubital vein at 12 + 0
to 14 + 0, 18 + 0 to 20 + 0, and 26 + 0 to 28 + 0 weeks of
gestation. After centrifugation serum samples were stored
at - 80°C until the analysis. Serum sFlt-1 and PlGF were
performed with automated ElecSys 2010 immunoanalyzer
utilizing new ElecSys sFlt-1 and PlGF assays (Roche
Diagnostics, Germany). In our laboratory the intra-assay
coefficient of variation (CV) for serum sFlt-1 was 2.8%,
calculated from duplicate patient samples in the concen-
tration range of 300–11 000 pg/ml (n = 30), and the inter-
assay CV < 1.4% (assay control samples, range 880 to
9100pg/ml). For serum PlGF the intra-assay CV was 2,3%
(n = 30, concentration range 16–500 pg/ml) and the
interassay CV < 1.9% (83-1960 pg/ml).
Statistical analysis
We analysed data with the SPSS 19.0 program. For com-
parisons between groups Students t-test and ANOVAwere used as appropriate. Bonferroni adjustment was
used for multiple comparisons. Since the sizes of the
groups differed, we used nonparametric Kruskal-Wallis
test, and for corrected: post hoc test pairwise compari-
sons with adjusted significance, to compare concentra-
tions (PlGF and sFlt-1) and sFlt-1/PlGF ratio between
the four groups.
For comparison of sequential changes of PlGF and
sFlt-1 concentrations, and sFlt-1/PlGF ratio between
groups from first to second, and from second to third
measurement, the change of the concentration or ratio
between measurements was calculated for each individ-
ual. For comparison of these changes between the four
groups we used nonparametric Kruskal-Wallis test.
Receiver-operating characteristic (ROC) analysis was
performed to determine the predictive value of PlGF and
sFlt-1/PlGF ratio at 18 + 0 to 20 + 0, and 26 + 0 to 28 + 0
weeks of gestation.
Results
Six women developed early-onset preeclampsia (onset
before 34 weeks of gestation), and twenty-one women
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gestation). In the late-onset group, eight women were
diagnosed with severe, and thirteen with non-severe
preeclampsia. In the early-onset group all six women
developed severe form of the disease.
The clinical characteristics of the study groups are
presented in Table 2.
There were no significant differences in the gestational
age at sampling between the four groups. In the early-
onset preeclampsia group the third samples were drawn
at 26.0-26.9 weeks of gestation, and diagnoses of
preeclampsia were made at 30.7-33.3 weeks of gestation.
We excluded the measurement at 27 weeks of gestation
in one woman who was diagnosed with early-onset
preeclampsia on the same day the blood sample was
drawn. In the other women proteinuria was not evident
at the time of blood sampling.
sFlt-1
Serum sFlt-1 concentration was significantly higher in
women who later developed early-onset preeclampsia
compared to women who developed late-onset pre-
eclampsia and to women in the two control groups at
26 + 0 to 28 + 0 weeks of gestation (Table 3). There were
no differences between women with late-onset pre-
eclampsia and control groups at any time point
(Figure 1). Those women who developed late-onset,Table 2 Baseline and pregnancy characteristics
Early-onset
preeclampsia n = 6 pre
Age at entry, years (SD) 31.2 (3.7)
Nulliparous, n (%) 3 (50%)
Body mass index before pregnancy, kg/m3
(geometric mean and 95% CI)
28.5 (21.8-37.2)** 3
Height, cm (SD) 162.5 (3.3)
Systolic blood pressure, mmHg (SD) 183 (15)**
Diastolic blood pressure, mmHg (SD) 111 (11)**
Proteinuria g/24 hours urine collection (SD) 5.7 (4.8)
Gestational age at delivery, weeks
(geometric mean and 95% CI)
32.8 (31.0-34.7)
Birth weight, g (SD) 1600 (490)
Birth weight sd score −2.2 (0.7)
Gestational age at first sample, weeks (SD) 12.6 (0.6)
Gestational age at second sample, weeks (SD) 19.3 (0.3)
Gestational age at third sample, weeks (SD) 26.3 (0.5)
Continuous, normally distributed data presented as mean (standard deviation, SD).
Continuous non-normally distributed data presented as geometric mean (95% conf
* p < 0.05 between groups.
** p < 0.05 for comparison with control women without risk factors.
‡ p < 0.05 for comparison with early onset preeclampsia group.
Early-onset preeclampsia is diagnosed before 34 + 0 weeks and days of gestation.
Late-onset preeclampsia is diagnosed after 34 + 0 weeks and days of gestation.severe preeclampsia (n = 8) had significantly higher sFlt-
1 concentration than women who were diagnosed with
late-onset, non-severe (n = 13) form of the disease at
12 + 0 to 14 + 0, 18 + 0 to 20 + 0, and 26 + 0 to 28 + 0
weeks of gestation (Table 4). In the late-onset pre-
eclampsia subgroup birthweight standard deviation (SD),
calculated according to Finnish standards [13], was signifi-
cantly lower in women with severe form of the disease
compared to women with non-severe form (birth weight
SD −1.0 (SD 0.9), 0.2 (SD 1.0) p = 0.01 respectively). The
body mass index (BMI) was significantly higher in women
who developed late-onset non-severe, preeclampsia, com-
pared to women who developed late-onset, severe pre-
eclampsia (BMI 33.6 (SD 7.0), 26.9 (SD 5.8), p = 0.03,
respectively).
The sequential changes in the sFlt-1 concentrations
between groups were not significant between the first
and the second measurements. The sequential change of
sFlt-1 concentration was significantly higher in the
early-onset preeclampsia group compared to the other
groups between the second and third measurements
(p = 0.002).
PlGF
Serum PlGF concentration was significantly lower in
women who went on to develop early-onset preeclamp-
sia compared to the other groups at 18 + 0 to 20 + 0, andLate-onset
eclampsia n = 21
Control women
with risk factors for
preeclampsia n = 26
Healthy control women
without risk factors for
preeclampsia n = 53
32.6 (5.0) 29.7 (6.0) 30.1 (4.6)
3 (17%)* 9 (35%) 34 (64%)
0.3 (27.1-33.7)** 27.8 (25.5-30.3)** 22.7 (22.0-23.4)
166.1 (4.8) 166.3 (6.6) 167.0 (5.5)
167 (16)** 140 (18)** 125 (13)
108 (8)** 91 (11)** 81 (7)
1.6 (2.0) - -
39.2 (38.6-39.7)‡ 40.0 (39.6-40.3)‡ 40.2 (39.8-40.6)‡
3360 (110)‡ 3480 (470)‡ 3460 (410)‡
−0.3 (1.1)‡ −0.2 (1.1)‡ −0.3 (0.8)‡
12.9 (0.6) 12.8 (0.7) 12.9 (0.6)
18.9 (0.5) 19.1 (0.6) 19.1 (0.6)
26.3 (0.6) 26.8 (0.8) 26.6 (0.8)
idence interval, CI).
Table 3 Concentrations of placental growth factor, soluble vascular endothelial growth factor receptor-1 and their
ratio in three different timepoints during pregnancy
sFlt-1 pg/ml
Weeks + days of gestation Early-onset preeclampsia Late-onset preeclampsia Controls with risk factors Healthy controls
12 + 0 to 14 + 0 1006.7 (715.0-1417.8) 924.5 (760.3-1124.4) 930.7 (803.2-1078.4) 1020.0 (875.0-1189.0)
18 + 0 to 20 + 0 1147.1 (592.2-2221.3) 918.1 (772.9-1090.7) 922.1 (743.4-1143.9) 969.8 (831.8-1128.3)
26 + 0 to 28 + 0 4847.3* (1318.6-17819.7) 1054.4 (887.2-1252.9) 1034.9 (876.2-1222.4) 1141.3 (975.9-1334.8)
PlGF pg/ml
Weeks + days of gestation Early-onset preeclampsia Late-onset preeclampsia Controls with risk factors Healthy controls
12 + 0 to 13 + 6 29.4 (21.0-41.1) 35.3 (30.3-41.3) 37.9 (31.6-45.5) 40.9 (35.3-47.3)
18 + 0 to 20 + 0 71.9* (52.8-98.1) 136.7 (112.7-165.8) 132.4 (113.8-154.0) 137.3 (120.9-155.9)
26 + 0 to 28 + 0 44.6* (25.6-77.8) 274.2 (222.4-338.1) 271.5 ‡ (224.9-327.6) 383.8 (332.3-443.3)
sFlt-1/PlGF ratio
Weeks + days of gestation Early-onset preeclampsia Late-onset preeclampsia Controls with risk factors Healthy controls
12 + 0 to 13 + 6 34.4 (22.2-53.3) 26.6 (21.3-33.2) 24.8 (19.7-30.5) 25.0 (22.3-28.0)
18 + 0 to 20 + 0 15.9 (6.6-38.8) 6.7 (5.2-8.7) 6.9 (5.3-8.9) 7.1 (6.1-8.2)
26 + 0 to 28 + 0 108.8* (40.5-292.1) 4.0 (3.0-5.4) 3.8 (3.0-4.9) 3.0 (2.5-3.6)
Concentrations (geometric mean, 95% confidence interval) of placental growth factor (PlGF) and soluble vascular endothelial growth factor receptor-1 (sFlt1), and
sFlt1/PlGF ratio at 12 + 0 to 14 + 0, 18 + 0 to 20 + 0, and 26 + 0 to 28 + 0 weeks of gestation in early-onset (N = 6), late-onset preeclampsia (N = 21), in controls with
risk-factors (N = 26), and in healthy controls without known risk-factors (N = 53).
* p < 0.05 compared to late onset preeclampsia, controls with risk factors and heathy control groups.
‡ p < 0.05 compared to healthy controls.
Early-onset preeclampsia is diagnosed before 34 completed weeks of gestation.
Late-onset preeclampsia is diagnosed after 34 completed weeks of gestation.
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not find any differences in the serum PlGF concentration
between the study groups at 12 + 0 to 14 + 0 weeks of
gestation, or between women with late-onset preeclamp-
sia and the two control groups at any time point
(Figure 1). At 26 + 0 to 28 + 0 weeks of gestation the
PlGF concentration in controls with risk factors was
significantly lower than in controls without risk factors.
There was a significant difference in the sequential
changes of the serum PlGF concentration between the
first and the second (p = 0.02), and the second and the
third (p < 0.001) measurement when the early- onset
preeclampsia group was compared with the late-onset
and the two control groups. Between the second and
third measurement the PlGF concentration increased
over 100% in the late-onset preeclampsia group and the
two control groups, whereas in the early-onset
preeclampsia group it decreased 40%.
sFlt-1/PLGF ratio
The serum sFlt-1/PlGF ratio at 26 + 0 to 28 + 0 weeks of
gestation was significantly higher in the early-onset pre-
eclampsia group compared to the other groups (Table 3).
We did not find any differences in the serum sFlt-1/PlGF
ratio between the four groups at 12 + 0-14 + 0 or at 18 + 0
to 20 + 0 weeks of gestation, or between the late-onset
preeclampsia group and control groups at any time
point (Figure 1).Between first and second measurements the sequential
changes between groups were not different. The sequen-
tial change of sFlt-1/PlGF ratio in the early-onset
preeclampsia group was significantly higher compared to
the late-onset preeclampsia and control groups between
second and third measurements (p = 0.002).
After adjusting for BMI before pregnancy the differ-
ences in sFlt-1, PlGF, or the sFlt-1/PlGF ratio between
groups remained unchanged.
We found a negative correlation between birth weight
SD score and the serum sFlt-1/PlGF ratio at all
timepoints in women who developed preeclampsia.
Correlation was strongest at 26 + 0 to 28 + 0 weeks of
gestation (Spearman’s correlation coefficient −0.403, p =
0.04; -0.452 p = 0.02, and −0.673, p = 0.0002 at 12 + 0
to14 + 0, 18 + 0 to 20 + 0, and 26 + 0 to 28 + 0 weeks of
gestation, respectively). We did not find any correlation
between birth weight SD score and the serum sFlt-1/PlGF
ratio in the two control groups.
Receiver operating characteristic analyses
Receiver operating characteristic (ROC) curves (Figure 2)
demonstrate the performance of these markers in pre-
diction of early-onset preeclampsia. PlGF (area under
the curve (AUC) 91.4%, p = 0.0007, 95% CI 83.4-99.5)
has a better predictive value at 18 + 0 to 20 + 0, weeks of
gestation than sFlt-1/PlGF ratio (AUC 78.6%, p = 0.02,
56.3-98.9). A cut-off point of PlGF concentration 83.9
050
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Figure 1 Box- and whisker plots. Box- and-whisker plot (mean, 95%
CI, range) of sFlt-1 and PlGF concentrations (pg/ml) and sFlt-1/PlGF
ratio at 12 + 0-14 + 0, 18 + 0-20 + 0, 26 + 0-28 + 0 weeks of gestation in
early-onset and late-onset preeclampsia groups and in controls with
risk factors and in healthy controls in the ’Prediction and Prevention of
Preeclampsia’ (PREDO) project.
Villa et al. BMC Pregnancy and Childbirth 2013, 13:110 Page 6 of 10
http://www.biomedcentral.com/1471-2393/13/110pg/ml finds women with future early-onset preeclampsia
with a 83.3% sensitivity and 91.1% specificity, with posi-
tive predictive value (PPV) 38% and negative predictive
value (NPV) 94%. At the 26 + 0 to 28 + 0 weeks of gesta-
tion sFlt-1/PlGF ratio performed slighty better than
PlGF (AUC 100.0%, p = 0.0007, 100.0-100.0, and 99.8%,p = 0.0008, 99.0-100.5, respectively), and better than
sFlt1-1 (AUC 94.4%, p = 0.003, 84.6-100.0). At 26 + 0 to
28 + 0 weeks of gestation all women who developed
early-onset preeclampsia and one woman who developed
severe late-onset preeclampsia had serum sFlt-1/PlGF
ratio over 30. All women who did not develop pre-
eclampsia or who developed late-onset, non-severe form
of the disease had sFlt-1/PlGF ratio under 15 at 26 + 0 to
28 + 0 weeks of gestation. If the cut-off point were set to
40, women who later develop early-onset preeclampsia
would have been found with 100% sensitivity and
specifity (PPV 100%, NPV100%). For PlGF with cut-off
point set to 90.4, PPV was 80% and NPV 100%.
Discussion
In this nested case–control study performed in high risk
women we found lower PlGF concentration from 18 + 0
to 20 + 0 weeks of gestation in sera of women who later
developed early-onset preeclampsia. Serum sFlt-1/PlGF
ratio over 40 at 26 + 0 to 28 + 0 weeks of gestation has
high specificity and sensitivity in identifying women who
developed early-onset disease. Women who were later
diagnosed with late-onset, severe form of preeclampsia
had significantly increased levels of sFlt-1 already at 12 + 0
to 14 + 0 weeks of gestation compared to women with
late-onset, non-severe form of the disease. This is a new
finding in a study with a small sample size and needs to
be confirmed in a larger study population.
We would like to emphasize that these findings are
likely to be specific to high risk women.
Earlier studies have reported that the ratio of sFlt-1/PlGF
is a better predictor of early preeclampsia than the two
markers alone [14]. We found that serum sFlt-1/PlGF ratio
was significantly higher from 26 + 0 to 28 + 0 weeks of
gestation in women who later developed early-onset
preeclampsia compared to the three other study
groups. However, in our study PlGF alone was a better
predictor of early pre-eclampsia at 18 + 0 to 20 + 0
weeks of gestation. In the study of Levine and co-
workers [6] sFlt-1/PlGF ratio was significantly higher
already from 17 to 20 weeks of gestation in women
who developed preterm preeclampsia. Moore Simas
and coworkers [15] found that sFlt-1/PlGF ratio mea-
sured at 22 to 26 weeks of gestation was highly pre-
dictive of early-onset preeclampsia. In these two
studies significantly increased sFlt-1/PlGF ratio was also
found at 25 to 30 weeks of gestation in women destined
to develop late-onset preeclampsia. In contrast, we did
not observe significant difference in sFlt-1/PlGF ratio be-
tween the late onset preeclampsia group and the two con-
trol groups at any of the measured time points. In our
study all women who were destined to develop early-onset
preeclampsia could be identified at 26 + 0 to 28 + 0 weeks
of gestation, 4.0 to 6.3 weeks before the diagnosis of
Table 4 Serum sFlt-1 concentration (pg/ml) (geometric mean, 95% confidence interval) at 12 + 0 - 14 + 0, 18 + 0 - 20 + 0,
and 26 + 0 - 28 + 0 weeks of gestation in women with late-onset preeclampsia group (onset ≥ 34 + 0 weeks of gestation)
Weeks + days
of gestation
Late-onset pre-eclampsia n = 21 Severe late-onset preeclampsia n = 8 Non-severe late-onset preeclampsia n = 13
12 + 0 – 14 + 0 925 (760–1124) 1330* (990–1670) 810 (620–1000)
18 + 0 – 20 + 0 918 (773–1091) 1220* (950–1490) 810 (650–980)
26 + 0 – 28 + 0 1054 (887–1253) 1480* (1080–1870) 920 (750–1090)
Severe preeclampsia was defined as systolic blood pressure ≥ 160 mmHg and/or diastolic ≥ 110 mmHg in two consecutive measurements and/or proteinuria > 5 g
in 24 hour urine collection.
* p < 0.05 compared to late-onset non-severe preeclampsia subgroup.
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http://www.biomedcentral.com/1471-2393/13/110preeclampsia, by sFlt1/PlGF ratio, cut-off point set so, that
no false positives existed. In other words, we were able to
identify the developing early-onset disease among the
high-risk population at least one month before the clinical
diagnosis was made. From the clinical perspective, these
findings are significant by helping obstetricians to make
decisions on the management of the high-risk women;
how intensive follow-up is required, whether hospita-
lization is essential, and whether it is necessary to be pre-
pared to early delivery in a tertiary care center.
Interestingly, recent studies have proposed that sFlt-1/PlGF
ratio may be useful not only as a predictor of preeclampsia
but also in the differential diagnosis of hypertensive diseases
of pregnancy, and, as well, serve as a prognostic parameterPlGF at 18th to 20th weeks
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Figure 2 Receiver operating characteristic curves. Receiver operating c
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(PREDO) project.in patients with established preeclampsia [16,17]. Verlohren
and coworkers proposed that sFlt-1/PlGF ratio may be used
in individualized risk stratification in patients with
clinical preeclampsia, and clinical management can be
adapted accordingly [17]. Rana and coworkers [18],
studied angiogenic factors in 616 women with a
suspected preeclampsia, and found that in early-onset
(<34 weeks) disease sFlt-1/PlGF ratio predicts adverse
outcome occurring within two weeks. Even in association
with the atypical presentation of preeclampsia, with relatively
normal blood pressure or with no proteinuria, sFlt-1/PlGF
ratio performed well. Rana and coworkers showed an inverse
correlation between sFlt-1/PlGF ratio and the remaining
duration of pregnancy.AUC 100%
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http://www.biomedcentral.com/1471-2393/13/110Many studies have demonstrated low levels of PlGF
already in the first trimester in women who later devel-
oped preterm or term preeclampsia [10,19-22]. Cowans
and coworkers [23] and Noori and coworkers [24] found
significantly lower PlGF levels from the first trimester of
pregnancy in women who later developed early-onset or
preterm preeclampsia, but not in women with term
preeclampsia. We found significant differences in the
serum PlGF concentrations between the early-onset
preeclampsia group and the three other study groups,
however, not earlier than 18 + 0 to 20 + 0 weeks of
gestation. We showed that at 18 + 0 to 20 + 0 weeks of
gestation, 7.3 to 13.4 weeks before the diagnosis, PlGF
could predict early-onset preeclampsia in our high-risk
population with an AUC 91.4%. The performance of PlGF
as a predictive marker improves over the course of preg-
nancy so that, 26 + 0 to 28 + 0 weeks of gestation, PlGF
has AUC 99.8% (PPV 80%, NPV 100%) in predicting
early-onset preeclampsia in this study population. How-
ever, during the second half of pregnancy, sFlt-1/PlGF
ratio performed even better (PPV 100%, NPV 100%).
Our study is in line with most earlier studies in finding
significant differences of sFlt-1 concentration between
women who are destined to develop preeclampsia and
controls not earlier than during the second half of preg-
nancy [15,20,25]. However, some studies have reported
elevated sFlt-1 concentration already from thirteen to
twenty weeks of gestation [18,26-28]. Analyses per-
formed using first trimester serum samples have resulted
in negative findings [19,21,22]. Vatten and coworkers
[29] studied a cohort consisting of 154 women who later
developed preterm preeclampsia (diagnosis before 37
weeks of gestation), 190 women with term preeclampsia
(diagnosis after 37 weeks of gestation) and 392 control
women. They found that sequential change of sFlt-1
concentration between first and second trimester
strongly predicts preeclampsia. Moreover, in the preterm
preeclampsia group the sequential change in sFlt-1 con-
centration was steeper than in the term preeclampsia
group. One major difference between our study and the
studies of others was that we did not find any differences
between the late onset preeclampsia and the two control
groups at any of the measured time points.
Vasoactive agents may behave differently not only in
early-onset and late-onset preeclampsia, but also in
severe and non-severe cases. This might reflect the
differences in pathogenesis of subtypes of preeclampsia.
Early-onset preeclampsia is considered more as a placen-
tal disease whereas late-onset more as a maternal
disease. Early-onset preeclampsia is considered a con-
sequence of abnormal placentation and it has often a
familial predisposition suggesting a genetic component
and a high recurrence risk [30]. In the early-onset form
of the disease placental insufficiency often results in fetalgrowth restriction. Late-onset disease emerges from
maternal predisposing risk factors, eg. metabolic factors,
associated with obesity, chronic hypertension, diabetes,
and interacting with a normal placenta [30]. Our finding
of significantly higher serum sFlt-1 concentration in
maternal serum already from 12 + 0 to 14 + 0 weeks of
gestation in women who developed late-onset, severe,
preeclampsia compared to women who developed late-
onset, non-severe form of the disease could reflect this
phenomenon. Women with late-onset, severe pre-
eclampsia gave birth to significantly lighter newborns,
whereas women with late-onset, non-severe form of the
disease had significantly higher BMI in early pregnancy
arguing for a metabolic etiology.
The strength of our study is a well-characterized
prospective cohort. However, we acknowledge that the
number of women who developed early-onset preeclamp-
sia was small even if we studied women with clinical risk
factors for preeclampsia. One limitation of our study is
that we do not have serum samples available after 30
weeks of gestation. Therefore we are not able to study
how these biomarkers behave close to the diagnosis of
late-onset preeclampsia. Our prospective study reflects
the true composition of early-onset and late-onset
preeclampsia in women at high-risk, which may explain
differences between the present and some earlier studies.
If the proportion of women with early-onset preeclampsia
compared to women with late-onset preeclampsia is
higher than usually observed in the clinical practise, and
the early- and late-onset preeclampsia groups are analysed
together, the results may be biased. Moreover, many
preanalytical and methodological differences may exist
between studies. These include the different sample
material (plasma or serum) and the storage and handling
of the samples. The assays may have a different specificity
and sensitivity and the study population may differ
between studies.
Conclusions
In conclusion, using serum PlGF we were able to
identify already before 20 weeks of gestation women
who will develop early-onset preeclampsia. Even more
accurately sFlt-1/PlGF ratio identified those women who
developed early-onset preeclampsia, weeks before the
onset of clinical disease.
The significantly increased serum sFlt-1 concentration
already from the 12 weeks of gestation in the late-onset,
severe preeclampsia compared to late-onset non-severe
preeclampsia suggests for different pathological back-
ground in the late-onset subgroup.
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